Skip to main content

Advertisement

Table 1 Characteristics of the patients according to SLC22A18 promoter methylation and protein expression status

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Variables N = 86 No. (%) SLC22A18 promoter methylation status, No. (%) P-value SLC22A18 protein expression, No. (%) P-value
Methylated N = 61(71) Unmethylated N = 25(29) Positive N = 36(42) Negative N = 50(58)
Gender
 Male 46(53) 36(59) 10(40) 0.11 21(58) 25(50) 0.45
 Fmale 40(47) 25(41) 15(60)   15(42) 25(50)  
Age (years)
 <45 13(15) 8(13) 5(20) 0.42 4(11) 9(18) 0.38
 ≥45 73(85) 53(87) 20(80)   32(89) 41(82)  
Performance status
 <90 39(45) 27(44) 12(48) 0.75 16(44) 23(46) 0.89
 ≥90 47(55) 34(56) 13(52)   20(56) 27(54)  
Extent of surgery
 Total 45(52) 34(56) 11(44) 0.32 19(67) 26(42) 0.94
 Not total 41(48) 27(44) 14(56)   17(33) 24(58)  
MGMT promoter
 Unmethylation 29(34) 18(30) 11(44) 0.20 12(33) 17(34) 0.95
 Methylation 57(66) 43(70) 14(56)   24(67) 33(66)  
TMZ therapy
 Yes 50(58) 37(61) 13(52) 0.46 23(64) 27(54) 0.36
 No 36(42) 24(39) 12(48)   13(36) 23(46)